Advances in the management of HPV-related oropharyngeal cancer
Patients with human papillomavirus- (HPV-) related oropharyngeal squamous cell carcinoma (OPSCC) have a better prognosis
than HPV-negative OPSCC when treated with standard high-dose cisplatin-based chemoradiotherapy. Consistent with this
assertion and due to younger age at diagnosis, novel approaches tominimize treatment sequelaewhile preserving survival outcomes
become of paramount importance. Here, we critically reviewed the evidence-based literature supporting the deintensification
strategies in HPV-related OPSCC management, including radiotherapy dose and/or volume reduction, replacement of cisplatin
radiosensitising chemotherapy, and the use of transoral surgery. Undoubtedly, further researches are needed before changing the
standard of care in this setting of patients.